Shining a LIGHT on myeloid cell targeted immunotherapy - Peeref (2024)

Article Immunology

LIGHT controls distinct homeostatic and inflammatory gene expression profiles in esophageal fibroblasts via differential HVEM and LT beta R-mediated mechanisms

Mario C. Manresa, Amanda Wu, Quan M. Nhu, Austin W. T. Chiang, Kevin Okamoto, Haruka Miki, Richard Kurten, Elaine Pham, Loan D. Duong, Nathan E. Lewis, Praveen Akuthota, Michael Croft, Seema S. Aceves

Summary: This study found that LIGHT promotes differentiation of esophageal fibroblasts toward an inflammatory phenotype and represses homeostatic gene expression via a LTβR-NIK-p52 NF-κB dominant pathway. HVEM and LTβR were identified as the receptors for LIGHT, with LTβR controlling all transcriptional effects through the NIK-p52 NF-κB pathway.

Review Biochemistry & Molecular Biology

Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition

Sunanda Singh, Hector J. J. Gomez, Shreya Thakkar, Samara P. P. Singh, Ashutosh S. S. Parihar

Summary: Anti-neoplastic agents for cancer treatment employ various mechanisms and when combined can effectively inhibit cancer growth. However, the development of acquired drug resistance often renders these agents ineffective. This study identifies at least 24 different anti-neoplastic agents that use the STAT3 signaling pathway to develop therapeutic resistance. Targeting STAT3 in combination with existing agents may be a successful strategy to prevent or overcome drug resistance.

Review Cell Biology

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Yasmin Abaza, Amer M. Zeidan

Summary: Immune checkpoint inhibitors have had a significant impact on the treatment of solid tumors, but there has been limited progress in myeloid malignancies. The low mutational burden of acute myeloid leukemia is a potential reason for the lack of response to T-cell harnessing ICIs. Targeting agents, such as magrolimab and sabatolimab, in combination with other drugs, have shown promising activity in early clinical trials.

Article Chemistry, Multidisciplinary

Boosting Cancer Immunotherapy via the Convenient A2AR Inhibition Using a Tunable Nanocatalyst with Light-Enhanced Activity

Wenqian Yu, Junlin Sun, Xiuyuan Wang, Shuyi Yu, Mingzhu Yan, Fuan Wang, Xiaoqing Liu

Summary: This study reports a convenient tumor-specific A2AR inhibition strategy to improve antitumor immune responses using a photo-modulated nanoreactor for spatiotemporally controlled oxygen supply. This nanoreactor not only relieves A2AR-mediated immunosuppression, but also enhances antitumor immunity through photothermal ablation of the tumor and immunogenic cell deaths.

Review Biochemistry & Molecular Biology

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials

Xianjing Chu, Wentao Tian, Ziqi Wang, Jing Zhang, Rongrong Zhou

Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by offering long-lasting responses and survival benefits. However, response rates vary among individuals and cancer types, leading to the proposal of dual ICI combination therapy. TIGIT, an inhibitory receptor associated with T-cell exhaustion, has diverse immunosuppressive effects and can synergize with PD-1/PD-L1 blockade to enhance tumor rejection. Preclinical studies have shown potential benefits, and clinical trials are underway to evaluate the safety and efficacy of TIGIT and PD-1/PD-L1 co-inhibition. Overall, co-inhibition of TIGIT and PD-1/PD-L1 represents a promising approach to improve outcomes for cancer patients treated with ICIs.

Article Immunology

Myeloid immune checkpoint ILT3/LILRB4/gp49B can co-tether fibronectin with integrin on macrophages

So Itoi, Naoyuki Takahashi, Haruka Saito, Yusuke Miyata, Mei-Tzu Su, Dai Kezuka, Fumika Itagaki, Shota Endo, Hiroshi Fujii, Hideo Harigae, Yuzuru Sakamoto, Toshiyuki Takai

Summary: Recent research has identified LILRB4 as an immune checkpoint that plays a role in regulating cellular activity in myeloid lineage cells. It has been found that LILRB4 can co-tether fibronectin (FN) in cooperation with integrin, forming a regulatory unit that affects cell signaling in macrophages.

Article Oncology

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression

Paul G. G. Pavicic Jr, Patricia A. Rayman, Shadi Swaidani, Amit Rupani, Vladimir Makarov, Charles S. Tannenbaum, Robert P. Edwards, Anda M. Vlad, C. Marcela Diaz-Montero, Haider Mahdi

Summary: The tumor microenvironment in ovarian cancer is characterized by immune suppression, and there is a need to find drugs that target these immunosuppressive networks and promote the recruitment of effector T cells. The study investigated the effect of the immunomodulatory cytokine IL12 alone or in combination with dual immune checkpoint inhibition on anti-tumor activity and survival. The findings suggest that the combination of IL12 and immune checkpoint inhibitors can improve clinical response in ovarian cancer by reversing immune suppression and enhancing T cell activity.

Article Oncology

Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia

Kailong Jiang, Xuemei Li, Chang Wang, Xiaobei Hu, Peipei Wang, Lexian Tong, Yutong Tu, Beijing Chen, Tingting Jin, Tao Wang, Hanlin Wang, Yubing Han, Renzhao Gui, Jianmin Yang, Tao Liu, Jia Li, Yubo Zhou

Summary: FLT3 inhibitors (FLT3i) are widely used for AML treatment, but adaptive and acquired resistance remains a challenge. This study found that CHK1 inhibitors can synergistically enhance the therapeutic effect of FLT3i in FLT3-mutated AML cells, overcoming adaptive resistance. Simultaneous targeting of FLT3 and CHK1 may overcome acquired and adaptive resistance.

Article Cell Biology

CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+T cells and immunosuppressive myeloid cells

Yuhan Zhang, Junyi Hu, Kai Ji, Shengpeng Jiang, Yang Dong, Lin Sun, Jun Wang, Guangyuan Hu, Dawei Chen, Ke Chen, Zhen Tao

Summary: This study investigates the changes of tumor-infiltrating immune cells after radiotherapy (RT) in a therapy-resistant murine tumor model and identifies CD39 inhibitor combined with RT as a potential strategy to decrease exhausted CD8+ T cells. Additionally, the combination of VISTA blockade and RT can reduce immunosuppressive myeloid cells, offering a rational combination therapy for non-small cell lung cancer (NSCLC).

Article Biotechnology & Applied Microbiology

From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma

Elena Simonetti, Serena Cutarella, Monica Valente, Tommaso Sani, Matteo Ravara, Michele Maio, Anna Maria Di Giacomo

Summary: Harnessing the immune system through immune-checkpoint blockade (ICB) has revolutionized the treatment of advanced melanoma patients. While anti-CTLA-4 and anti-PD-1 monoclonal antibodies have shown remarkable success, many patients still do not respond to therapy. To improve ICB efficacy, researchers are investigating the use of co-stimulatory molecules in addition to immune-checkpoint inhibitors. Understanding the clinical outcomes of patients exposed to these therapies may lead to more effective treatment strategies.

Article Oncology

c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28-and IL-2-independent co-stimulation

Yuquan Xiong, Meriem Taleb, Kyohei Misawa, Zhaohua Hou, Srijita Banerjee, Alfredo Amador-Molina, David R. R. Jones, Navin K. K. Chintala, Prasad S. S. Adusumilli

Summary: Introducing the c-Kit D816V mutation into CAR T cells enhances their activity and cytotoxicity against solid tumors, and can be controlled by tyrosine kinase inhibitors.

Article Engineering, Electrical & Electronic

Effect of Adjacent Lateral Inhibition on Light and Electric-Stimulated Synaptic Transistors

Jumei Zhou, Jiaquan Dai, Shichen Weng

Summary: Lateral inhibition is a fundamental principle in the nervous system for information processing, and it plays a crucial role in various sensory systems. In this study, synaptic transistors with lateral gates were developed on a plastic substrate to emulate lateral inhibition. The effects of lateral inhibition on light-induced and electric-induced synaptic characteristics were investigated, and the results demonstrated that lateral inhibition can enhance paired pulse facilitation (PPF) gain ratio, amplify current variation ratio in light-induced channel excitability, and modulate the duration of light-induced memory.

Review Hematology

Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways

Jan Philipp Bewersdorf, Rory M. Shallis, Amer M. Zeidan

Summary: Immune checkpoint inhibitors have shown mixed results in clinical trials in patients with acute myeloid leukemia and myelodysplastic syndromes, but there is optimism for the future of this field. Advances in understanding the immunologic landscape, potential biomarkers, and resistance mechanisms provide hope, but challenges such as the lack of validated biomarkers and the development of safe combination therapies still need to be addressed.

Article Biochemistry & Molecular Biology

p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain)

Phaik Ju Teoh, Omer An, Tae-Hoon Chung, Thamil Vaiyapuri, Anandhkumar Raju, Michal M. Hoppe, Sabrina H. M. Toh, Wilson Wang, Ming Chun Chan, Melissa J. Fullwood, Anand D. Jeyasekharan, Vinay Tergaonkar, Leilei Chen, Henry Yang, Wee Joo Chng

Summary: Recurrent cytogenetic abnormalities are key characteristics of multiple myeloma (MM), with patients harboring both 17p13(del) and 1q21(gain) associated with the worst prognosis. These patients exhibit high genomic instability and a heightened sensitivity to Chk1 inhibition, suggesting a potential therapeutic vulnerability for targeted treatment.

Article Multidisciplinary Sciences

Remote-refocusing light-sheet fluorescence microscopy enables 3D imaging of electromechanical coupling of hiPSC-derived and adult cardiomyocytes in co-culture

L. Dvinskikh, H. Sparks, L. Brito, K. T. MacLeod, S. E. Harding, C. Dunsby

Summary: Improving cardiac function through stem-cell regenerative therapy requires integration of transplanted cells with host tissue, which can be visualized using high-resolution 3D imaging. A custom light-sheet fluorescence microscope was used to study calcium dynamics in co-cultures of rat and human cardiomyocytes. The two cell types showed synchronized calcium transients and contraction, and electromechanical coupling improved with co-culture duration.

Meeting Abstract Oncology

Agonist redirected checkpoint (ARC), SIRPα-Fc-CD40L, for cancer immunotherapy

George Fromm, Suresh de Silva, Kellsey Johannes, Arpita Patel, Josiah C. Hornblower, Taylor H. Schreiber

Article Oncology

CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity

Suresh de Silva, George Fromm, Casey W. Shuptrine, Kellsey Johannes, Arpita Patel, Kyung Jin Yoo, Kaiwen Huang, Taylor H. Schreiber

Meeting Abstract Oncology

LIGHT (TNFSF14) CO-STIMULATION ENHANCES MYELOID CELL ACTIVATION AND ANTI-TUMOR IMMUNITY IN THE SETTING OF PD-1 AND TIGIT CHECKPOINT BLOCKADE

George Fromm, Kyung Jin Yoo, Kellsey Johannes, Casey Shuptrine, Zach Opheim, Arpita Patel, Haley Andreasen, Jaya Miriyala, Suresh De Silva, Taylor Schreiber

Article Immunology

Cutting Edge: Bispecific gd T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vg9Vd2+T Cells in the Presence of Costimulation by CD28 or NKG2D

Anne Y. Lai, Arpita Patel, Faraha Brewer, Kinsley Evans, Kellsey Johannes, Louis E. Gonzalez, Kyung Jin Yoo, George Fromm, Keith Wilson, Taylor H. Schreiber, Suresh de Silva

Summary: Vg9Vd2+ T cell-targeted immunotherapy is a promising approach for cancer treatment. This study identified BTN2A1 and BTN3A1 as signal 1 molecules for Vg9Vd2 TCR activation and found that a costimulatory signal is required for optimal activation. Furthermore, a bispecific gd T cell engager BTN2A1/3A1-Fc-CD19scFv was shown to enhance killing of CD19+ lymphoma cells, indicating the importance of costimulatory ligands on tumor cells. These findings highlight the similarities between signal 1 and signal 2 requirements in ab and gd T cell activation and demonstrate the potential of heterodimeric BTNs for targeted activation of gd T cells.

Review Immunology

Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists

George Fromm, Suresh de Silva, Taylor H. Schreiber

Summary: The extracellular domain of tumor necrosis factor receptors (TNFR) needs to assemble into a hom*otrimeric quaternary structure in order to initiate signaling. Synthetic agonists targeting TNF receptors have potential clinical benefits in amplifying immune responses, but their translation into human clinical studies has been limited and raised questions about the biology of TNF receptors.

Article Immunology

LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade

Kyung Jin Yoo, Kellsey Johannes, Louis E. Gonzalez, Arpita Patel, Casey W. Shuptrine, Zachary Opheim, Karen Lenz, Kristen Campbell, Thuy-Ai Nguyen, Jayalakshmi Miriyala, Connor Smith, Ashlyn McGuire, Yi-Hsuan Tsai, Fatima Rangwala, Suresh de Silva, Taylor H. Schreiber, George Fromm

Summary: Coinhibition of TIGIT and PD-1/PD-L1 may lead to improved response rates in non-small cell lung cancer with high PD-L1 expression. TIGIT can inhibit tumor growth by activating the PVR signaling pathway, which is directly inhibited by PD-1. Immune costimulation through TIGIT blockade may broaden the clinical utility in PD-L1(low) or checkpoint inhibition-resistant tumors.

Meeting Abstract Oncology

Antigen-specific targeting of tissue-resident gamma delta T cells with recombinant butyrophilin heterodimeric fusion proteins.

Suresh de Silva, George Fromm, Anne Lai, Louis Gonzalez, Arpita Patel, Kyung Jin Yoo, Kellsey Johannes, Kinsley Evans, Keith Wilson, Taylor H. Schreiber

Meeting Abstract Oncology

The development of an in vivo model of checkpoint acquired resistance, reveals a program of interferon hyperstimulation, resulting in dysregulation of MHC class I, protein translation/trafficking, and other unique pathways, that may be useful for guiding clinical strategy in patients with phenotypic similarities.

George J. Fromm, Danish Memon, Suresh de Silva, Kyung Jin Yoo, Kellsey Johannes, Casey Shuptrine, Jaya Miriyala, Arpita Patel, Fatima Rangwala, Zachary Opheim, Thuy-Ai Nguyen, Louis Gonzalez, Fatima Rangwala, Taylor H. Schreiber, Matthew D. Hellmann, Martin L. Miller, Taylor H. Schreiber

Meeting Abstract Oncology

IN VIVO EXPANSION OF GAMMA DELTA T CELLS BY A CD19-TARGETED BUTYROPHILIN HETERODIMER LEADS TO ELIMINATION OF PERIPHERAL B CELLS

Suresh De Silva, George Fromm, Louis Gonzalez, Arpita Patel, Kyung Yoon, Zachery Opheim, Robert Farmer, Dean Chamberlain, Taylor Schreiber

Meeting Abstract Oncology

Co-stimulation of OX40 or LTβR reprograms exhausted lymphocytes to acquire an effector phenotype in the setting of combined TIGIT and checkpoint blockade

George Fromm, Suresh De Silva, Arpita Patel, Kyung Jin Yoo, Kellsey Johannes, Kaiwen Huang, Taylor Schreiber

Meeting Abstract Oncology

Development and characterization of SL-115154 (CSF1R-Fc-CD4OL) for cancer immunotherapy

Taylor H. Schreiber, George Fromm, Suresh De Silva, Arpita Patel, Kellsey Johannes, Kyung Jin Yoo, Kaiwen Huang

Meeting Abstract Immunology

Agonist Redirected Checkpoint (ARC), SIRPα-Fc-CD40L, for Cancer Immunotherapy

George Fromm, Suresh de Silva, Arpita Patel, Kellsey Johannes, Josiah Hornblower, Taylor H. Schreiber

Meeting Abstract Immunology

Agonist Redirected Checkpoint (ARC), TIM3-Fc-OX40L, for Cancer Immunotherapy

George Fromm, Suresh de Silva, Arpita Patel, Kellsey Johannes, Josiah Hornblower, Taylor H. Schreiber

Meeting Abstract Immunology

Gp96-Ig/Costimulator Combination Platform Improves T Cell Priming, Enhances Immunity and Memory

Louis E. Gonzalez, Louise Giffin, Jason Rose, George Fromm, Suresh Da Silva, Taylor H. Schreiber, Rahul Jasuja, Jeff Hutchins

Article Oncology

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo

Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.

Article Oncology

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial

Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi

Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.

Article Oncology

Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri

Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.

Article Oncology

Impact of colorectal cancer screening on survival after metachronous metastasis

Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman

Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.

Article Oncology

Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY)

Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna fa*gotti, Giovanni Scambia

Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.

Article Oncology

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies

Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.

Article Oncology

Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study

Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond

Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.

Letter Oncology

Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity

Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng

Article Oncology

Deep learning based histological classification of adnex tumors

Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank

Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.

Article Oncology

FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction

Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen

Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.

Article Oncology

Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases

Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li

Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.

Article Oncology

Peptide absent sequences emerging in human cancers

Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares

Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.